<DOC>
	<DOCNO>NCT02367755</DOCNO>
	<brief_summary>Therapeutic hypothermia proven significantly improve survival neurological prognosis patient resuscitate cardiac arrest . Propofol report exhibit potential mitigate ischemia-reperfusion injury via antioxidative , anti-inflammatory neuroprotective mechanism . This study investigate potential propofol improve survival neurological prognosis era therapeutic hypothermia .</brief_summary>
	<brief_title>Therapeutic Hypothermia With Propofol Survival Neurological Prognoses After Cardiac Arrest</brief_title>
	<detailed_description>Cardiac arrest cardiopulmonary resuscitation ( CPR ) specific model global ischemia/reperfusion ( I/R ) injury . Among organ system , brain least tolerable ischemic insult I/R injury , account usually poor survival neurological outcome patient even initial success resuscitation . Therapeutic hypothermia ( TH ) proven significantly improve survival neurological prognosis patient resuscitate cardiac arrest . It recommend standard therapy post-resuscitation care since 2002 . In past year , NTUH FEMH actively promote application TH post-resuscitation care , achieve important progress . Based , investigator seek improve survival neurological outcome group patient . Among therapy potential additive synergistic protective mechanism , propofol extensively study , show exhibit great potential mitigate ischemia-reperfusion injury via antioxidative , anti-inflammatory neuroprotective mechanism . As sedative basic requirement TH accord technical ethical concern , combination propofol TH justify highly anticipate . The investigator therefore seek investigate potential propofol improve survival neurological prognosis era therapeutic hypothermia . Methods : This .is prospective , single-blinded randomized clinical trial . The inclusion criterion include : ( 1 ) non-traumatic cardiac arrest ( 2 ) regain consciousness return spontaneous circulation ( ROSC ) ( 3 ) age &gt; =20 year old &lt; = 90 year old . The exclusion criterion include ( 1 ) age &lt; 20 y/o &gt; 90 y/o ( 2 ) pregnancy ( 3 ) traumatic cardiac arrest ( 4 ) fail achieve ROSC ( 5 ) conscious recovery ROSC ( 6 ) contraindication TH , massive bleeding , infection , etc ( 7 ) terminal disease ( 8 ) conscious disturbance cardiac arrest ( 9 ) fail obtain informed consent ( 10 ) family refuse undergo clinical trial . The study divide two group : ( 1 ) Lorazepam group : lorazepam infusion rate 0.5 mg/kg/hr TH . ( 2 ) Propofol group : propofol infusion rate 3 mg/kg/hr TH . The primary endpoint ( 1 ) survival ( 2 ) neurological outcome indicate cerebral performance category ( CPC ) scale . The secondary endpoint include ( 1 ) 99mTc ECD scan ( perfusion viability ) , ( 2 ) clinical EEG evidence seizure . The blood pressure heart rate continuously monitor TH propofol/lorazepam infusion . Expected Results : ( 1 ) Test propofol improve survival neurological outcome post-CPR patient undergo TH ( 2 ) Test propofol improve cerebral perfusion neuron viability post-CPR patient undergo TH ( 3 ) Test propofol reduces incidence severity seizures post-CPR , ( 4 ) Test propofol significantly influence hemodynamics combine TH Clinical Implications : Propofol clinically available sedative agent . If trial demonstrate propofol improves survival neurological outcome post-resuscitation patient undergo TH , would become important evidence justify implementation clinical practice</detailed_description>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Inclusion criterion : 1. nontraumatic cardiac arrest 2. regain consciousness return spontaneous circulation ( ROSC ) 3. age &gt; =20 year old &lt; = 90 year old . Exclusion criterion : 1. age &lt; 20 y/o &gt; 90 y/o 2. pregnancy 3. traumatic cardiac arrest 4. fail achieve ROSC 5. conscious recovery ROSC 6. contraindication TH , massive bleeding , infection , etc 7. terminal disease 8. conscious disturbance cardiac arrest 9. fail obtain informed consent 10. family refuse undergo clinical trial 11. allergy propofol lorazepam .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cardiopulmonary resuscitation</keyword>
	<keyword>cardiac arrest</keyword>
	<keyword>therapeutic hypothermia</keyword>
	<keyword>propofol</keyword>
	<keyword>lorazepam</keyword>
	<keyword>cerebral perfusion</keyword>
	<keyword>electroencephalography</keyword>
</DOC>